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Objective: Mass drug administration (MDA) with azithromycin for trachoma elimination reduces naso-
pharyngeal carriage of Streptococcus pneumoniae in the short term. We evaluated S. pneumoniae carried
in the nasopharynx before and after a round of azithromycin MDA to determine whether MDA was
associated with changes in pneumococcal population structure and resistance.
Methods: We analysed 514 pneumococcal whole genomes randomly selected from nasopharyngeal
samples collected in two Gambian villages that received three annual rounds of MDA for trachoma
elimination. The 514 samples represented 293 participants, of which 75% were children aged 0e9 years,
isolated during three cross-sectional surveys (CSSs) conducted before the third round of MDA (CSS-1)
and at 1 (CSS-2) and 6 (CSS-3) months after MDA. Bayesian Analysis of Population Structure (BAPS) was
used to cluster related isolates by capturing variation in the core genome. Serotype and multilocus
sequence type were inferred from the genotype. Antimicrobial resistance determinants were identified
from assemblies, including known macrolide resistance genes.
Results: Twenty-seven BAPS clusters were assigned. These consisted of 81 sequence types (STs). Two
BAPS clusters not observed in CSS-1 (n ¼ 109) or CSS-2 (n ¼ 69), increased in frequency in CSS-3
(n ¼ 126); BAPS20 (8.73%, p 0.016) and BAPS22 (7.14%, p 0.032) but were not associated with antimi-
crobial resistance. Macrolide resistance within BAPS17 increased after treatment (CSS-1 n ¼ 0/6, CSS-2/3
n ¼ 5/5, p 0.002) and was carried on a mobile transposable element that also conferred resistance to
tetracycline.
Discussion: Limited changes in pneumococcal population structure were observed after the third round
of MDA, suggesting treatment had little effect on the circulating lineages. An increase in macrolide
resistance within one BAPS highlights the need for antimicrobial resistance surveillance in treated vil-
lages. Rebecca A. Gladstone, Clin Microbiol Infect 2020;▪:1
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Trachoma, caused by ocular infection with Chlamydia tracho-
matis, remains the leading infectious cause of blindness worldwide.
The World Health Organization recommended strategy for
trachoma elimination includes mass drug administration (MDA)
with the broad-spectrum antibiotic azithromycin [1,2].
Azithromycin MDA for trachoma control has been shown to
have important collateral benefits [3e5]. In Ethiopia the mortalityof Clinical Microbiology and Infectious Diseases. This is an open access article under
n with azithromycin for trachoma elimination and the population
biology and Infection, https://doi.org/10.1016/j.cmi.2020.07.039
R.A. Gladstone et al. / Clinical Microbiology and Infection xxx (xxxx) xxx2rate of children residing in treated villages was lower than that in
untreated villages [3]. Another trial conducted in Niger, Tanzania
and Malawi found biannual MDA with azithromycin significantly
reduced all-cause under-5 mortality compared with placebo [5].
Substudies in that trial found an increased proportion of macrolide
resistance after treatment in nasopharyngeal Streptococcus pneu-
moniae [6] and an increased frequency of macrolide resistance
determinants in the gut after treatment [7]. While the mechanism
underlying the reduction in mortality is still not clear, it may be
partially due to the significant reduction of S. pneumoniae carriage
[8e11]. Other studies on azithromycin MDA for trachoma control
have also found an increased risk of azithromycin-resistant pneu-
mococcal carriage [12,13]. This has led to cautionary notes about
the spread of antimicrobial resistance and requirements for
adequate surveillance following MDA [14,15].
However, the effect of MDA on pneumococcal carriage is short
lived with rates returning to original levels within a few months of
treatment [16]. It is unclear whether the same pneumococcal
strains return after treatment, or whether azithromycin MDA se-
lects for previously suppressed strains. An Ethiopian study
following intensive MDA documented decreased serotype diversity
associated with a significant rise in macrolide resistance. The study
concluded that clonal expansion of resistant isolates caused a
decrease in the diversity of the population [17].
Bayesian Analysis of Population Structure (BAPS) is commonly
used to define pneumococcal population structure in sequencing
studies assessing the impact of medical inventions [18e20]. BAPS
uses variation across the genome to cluster isolates into related
groups, with increased power to detect small changes in prevalence
over serotype or multilocus sequence type (MLST).
In The Gambia, we previously showed that azithromycin MDA
resulted in a significant yet transient decrease in pneumococcal
carriage with prevalence falling from 43% before the final round of
MDA to 19% 1month followingMDA [11]. Within 6months carriage
prevalence had returned to 46% but was not associated with a
significant rise in azithromycin resistance. We aimed to determine
if there were changes in pneumococcal population structure
following the third round of MDA with relation to azithromycin
resistance.
Methods
The Partnership for the Rapid Elimination of Trachoma (PRET)
study (ClinicalTrials.gov NCT00792922) was a cluster randomized
controlled trial [21e23]. Briefly, the study compared the effective-
ness of three annual rounds versus one round of azithromycin MDA
in reducing the prevalence of trachoma. Residents of a community
were eligible for treatment with a single oral dose of 20 mg/kg
azithromycin to a maximum of 1 g. A pneumococcal carriage study
was nested within PRET [11] and was carried out in eight of the
villages in the larger trial. This included two villages that had been
randomized within PRET to three annual rounds of MDA (3
treatment arm) and six villages that received a single treatment
round (1 treatment arm). Pneumococcal population structurewas
assessed by selecting isolates for sequencing from the two villages
thatwere randomized to three annual treatment rounds. All villages
had participated in a cluster (by village) randomized trial control
arm of a seven-valent pneumococcal vaccine (PCV-7) between 2006
and 2008, before PCV-7 introduction in The Gambia [22]. All chil-
dren under the age of 30 months when the vaccine trial started,
thosebornduring the trial periodor thosewhomoved into the study
villages during the trial period were vaccinated with PCV-7.
During the pneumococcal carriage study, three cross-sectional
surveys (CSSs) were conducted in the 3 treatment arm of
PRET: CSS-1 (June 2010), 1 month prior to the third annual roundPlease cite this article as: Gladstone RA et al., Mass drug administratio
structure of Streptococcus pneumoniae in the nasopharynx, Clinical Microof MDA; CSS-2 (July 2010), 1 month following the third round of
MDA; and CSS-3 (December 2010), 6 months following the third
round (Fig. 1), after PCV-7 was introduced into the Gambian
Expanded Programme on Immunization in August 2009. Census
data were gathered in the week prior to the study onset. At CSS-1,
all censused children <15 years of age, present at the time of
sampling were invited to participate. For individuals 15 years,
150 were randomly selected for participation. At CSS-2 and CSS-3,
participation was restricted to those who had received azi-
thromycin during the third round of MDA in July 2010; all cen-
sused and treated children <15 years of age and 150 randomly
selected treated individuals 15e82 years were invited to
participate. The study adhered to the tenants of the Declaration of
Helsinki and was approved by The Gambia Government/Medical
Research Council Unit, The Gambia Joint Ethics Committee. Writ-
ten, informed consent was obtained from all participants. In the
case of minors, informed consent was obtained from the parent or
guardian.
Nasopharyngeal swabs (NPSs) were collected from 1175 par-
ticipants. NPS samples were collected using calcium alginate swabs
and inoculated into sterile vials containing skimmed-milke-
tryptoneeglucose glycerol transport medium. Samples were kept
on wet ice, refrigerated within 8 hours of collection and moved to
long-term storage at e70C within 24 hr of collection. NPS samples
were thawed at room temperature and 10 mL of medium was
inoculated onto Columbia agar supplemented with 5% sheep blood
and 5 mg/mL gentamicin (GBA). Inoculated plates were incubated
for 18e24 hr at 35C in 5% CO2. Presumptive S. pneumoniae colonies
were identified on the basis of morphology and optochin sensitivity
and up to four pneumococcal isolates representing varying colony
morphologies were cultured from positive NPS [11]. In total 1455
pneumococcal isolates were archived. A random 720 isolates were
selected for whole genome sequencing, restricted such that CSS-1
to 3 would be equally represented by children less than 5 years of
age, between 5 and 10 years of age and by participants over 10 years
of age. Isolates were screened for sensitivity to azithromycin by disc
diffusion. Isolates showing intermediate or resistant phenotypes
were further analysed by minimal inhibitory concentration (MIC)
using the E-test (Biomerieux).
Isolates randomly selected for sequencing were revived on GBA
and incubated overnight at 37C with 5% CO2. A single colony was
inoculated into 20 mL of ToddeHewitt broth containing 0.5% yeast
extract and re-incubated overnight. The overnight broth cultures
were pelleted by centrifugation and DNA was extracted using the
Wizard Genomic DNA Purification Kit (Promega Corporation,
Madison, WI, USA). DNA quantification was performed using
PicoGreen staining (Invitrogen, Paisley, UK). DNA extracts from 533
samples that could be revived and that yielded at least 500 ng of
DNAwere shipped, on dry ice, to the Wellcome Sanger Institute for
sequencing.
DNAwas sequenced on Illumina Hiseq platforms using pair-end
read lengths of 100 base pairs. Data for 514 sequenced isolates were
not heavily contaminated, had sufficient coverage to be analysed
and were confirmed as pneumococci. These samples represented
293 participants, of which 75% were children aged 0e9 years. Core
genes were defined using Roary [24]. The core alignment was
clustered using hierBAPS [25] to determine BAPS clusters, with a
second level of hierarchical clustering to determine BAPS sub-
clusters. The core alignment was reduced to single nucleotide
polymorphism (SNP) sites [26] and used to produce a midpoint
rooted RAxML phylogeny [27]. SNPs were reconstructed on the tree
using the acctran parsimony method. Serotypes were inferred from
the genomic data [28]. Antimicrobial resistance identification by
assembly (ARIBA) [29] and a pneumococcal typing tool [30] were
used to screen isolates for known resistance conferring genes andn with azithromycin for trachoma elimination and the population
biology and Infection, https://doi.org/10.1016/j.cmi.2020.07.039
Fig. 1. Study flow. Study flow of sampling and number of isolates available from nasopharyngeal swabs (NPS) in each cross-sectional survey (CSS) and overall.
R.A. Gladstone et al. / Clinical Microbiology and Infection xxx (xxxx) xxx 3mutations. Metadata for 514 isolates with European Nucleotide
Archive (ENA) accession numbers are available (please see sup-
plementary material) and paired with the phylogenetic tree
(https://microreact.org/project/MDA_pneumo).
Only one representative of each sequence type (ST) from the
same individual and timepoint was included in the statistical
analysis as these represented duplicated sampling from multiple
colonies from an individual NPS, leaving 304 independent isolates
of the 514 appropriate to include in statistical analysis. The diversity
of serotypes and STs was assessed using Simpson's Diversity index,
where 1 represents infinite diversity and 0 no diversity.
The proportion for each serotype/genotype within each CSS was
calculated. Confidence intervals were calculated at 95% using the
exact method of biconf in the Hmisc package, R v3.4.1 [31]. ThePlease cite this article as: Gladstone RA et al., Mass drug administratio
structure of Streptococcus pneumoniae in the nasopharynx, Clinical Microtwo-tailed Fisher exact test was used to detect significant changes
in the proportion of each serotype/genotype between two time-
points when at least five isolates represented the serotype/geno-
type. p Values were adjusted for multiple testing using the ‘BH’
method of p.adjust in the stats package, R v3.4.1 [32]. The 304 in-
dependent isolates provided 80% power with 95% confidence to
detect a fivefold increase in a BAPS cluster between CSS-1 and CSS-
2 and fourfold increase between CCS-1 and CSS-3.
Results
During the initial carriage study, 1455 isolates were recovered
from participants in the 3 treatment arm. Of these, 720 were
randomly selected for sequencing. In total 533 of these weren with azithromycin for trachoma elimination and the population
biology and Infection, https://doi.org/10.1016/j.cmi.2020.07.039
R.A. Gladstone et al. / Clinical Microbiology and Infection xxx (xxxx) xxx4successfully revived from glycerol stocks and yielded at least 500
ng of DNA. Quality sequence data were obtained for 514 isolates.
After excludingmultiple instances of a ST from the same participant
and time point, 304 independent isolates were available to assess
temporal distribution and diversity (Fig. 1).Population structure
BAPS revealed 27 BAPS clusters (Fig. 2). We did not observe
significant changes in the proportion of isolates in any BAPS cluster
between CSS-1 and CSS-2 (Table 1). A significant increase between
CSS-1 and CSS-3 was observed for BAPS20 (p 0.016) and BAPS22 (p
0.032). Neither BAPS cluster was observed at CSS-1 or CSS-2
(Table 1) and comprised exclusively serotype 16F (ST8949/13858)
and 45 (ST2831), respectively, in CSS-3. A second round of BAPS
clustering identified 81 BAPS subclusters. None was observed to
significantly change in proportion (Table S1). We observed 36Fig. 2. Distribution of isolates predicted to be resistant to erythromycin across BAPS clust
reconstructed on the tree of the 304 randomly sampled isolates. Scale is in SNPs. The nodes a
BAPS10 (red) is the bin cluster representing un-clustered isolates spread across the tree. BA
(BAPS27). The middle ring depicts the CSS in which the isolate was collected CSS-1(green
susceptibility to erythromycin across the tree, resistant (red), sensitive (green). A fully inte
9861bdea.
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structure of Streptococcus pneumoniae in the nasopharynx, Clinical Microserotypes and 81 STs. No serotype or ST was found to vary signifi-
cantly in their proportion of the population (Tables S2 and S3). At
each CSS, serotype and ST diversity was high. No decrease in di-
versity was seen following the round of MDA (Table 2).Antimicrobial resistance
No isolates carried macrolide resistance genes in CSS-1
(n ¼ 109), 2/69 were observed in CSS-2 and 4/126 in CSS-3; this
represented a non-significant increase (p 1). However, 5/6 were
serotype 20, ST1794 strains of BAPS17. They carried the macrolide
efflux genesmef(A) andmsr(D) [33] (Fig. 2). These were carried in a
Tn2010 element, which also carried the tetracycline resistance gene
tet(M) [23]. The isolates also had known co-trimoxazole resistance
mutations in FolA and FolP. The proportion of BAPS17 isolates
predicted to be erythromycin, tetracycline and co-trimoxazole
resistant within BAPS17 increased significantly between CSS-1ers and CSS. Phylogenetic tree of single nucleotide polymorphisms in the core genes
nd innermost ring represent the first level BAPS clusters which are annotated, of which
PS cluster nomenclature represents the largest (BAPS1) through to the smallest cluster
), CSS-2 (yellow) CSS-3 (purple). The outermost ring depicts each isolate's predicted
ractive view of this figure is available at https://microreact.org/project/MDA_pneumo/
n with azithromycin for trachoma elimination and the population
biology and Infection, https://doi.org/10.1016/j.cmi.2020.07.039
Table 1
Proportion of isolates belonging to BAPS clusters at each CSS
BAPS clusters CSS-1 CSS-2 CSS-1 vs CSS-2 CSS-3 CSS-1 vs CSS-3
Proportion (n ¼ 109) Proportion (n ¼ 69) p value Proportion (n ¼ 126) p value
% (95% CI) % (95% CI) (direction) % (95% CI) (direction)
1 6.42 (2.62, 12.78) 5.8 (1.6, 14.18) 1.000 3.17 (0.87, 7.93) 0.599
2 5.5 (2.05, 11.6) 7.25 (2.39, 16.11) 1.000 2.38 (0.49, 6.8) 0.599
3 8.26 (3.85, 15.1) 8.7 (3.26, 17.97) 1.000 3.97 (1.3, 9.02) 0.481
4 1.83 (0.22, 6.47) 7.25 (2.39, 16.11) 0.552 1.59 (0.19, 5.62) NA
5 2.75 (0.57, 7.83) 2.9 (0.35, 10.08) 1.000 0.79 (0.02, 4.34) NA
6 0.92 (0.02, 5.01) 5.8 (1.6, 14.18) 0.552 0 (0, 2.89) NA
7 11.01 (5.82, 18.44) 1.45 (0.04, 7.81) 0.262 2.38 (0.49, 6.8) 0.071
8 7.34 (3.22, 13.95) 10.14 (4.18, 19.79) 1.000 11.11 (6.21, 17.94) 0.599
9 0.92 (0.02, 5.01) 0 (0, 5.21) NA 2.38 (0.49, 6.8) NA
10a 13.76 (7.91, 21.68) 10.14 (4.18, 19.79) 1.000 20.63 (13.94, 28.75) 0.481
11 0 (0, 3.33) 4.35 (0.91, 12.18) NA 0 (0, 2.89) NA
12 2.75 (0.57, 7.83) 2.9 (0.35, 10.08) 1.000 1.59 (0.19, 5.62) 0.808
13 2.75 (0.57, 7.83) 1.45 (0.04, 7.81) NA 0 (0, 2.89) NA
14 5.5 (2.05, 11.6) 5.8 (1.6, 14.18) 1.000 4.76 (1.77, 10.08) 1.000
15 0.92 (0.02, 5.01) 1.45 (0.04, 7.81) NA 2.38 (0.49, 6.8) NA
16 1.83 (0.22, 6.47) 2.9 (0.35, 10.08) NA 7.94 (3.87, 14.11) 0.158
17 5.5 (2.05, 11.6) 2.9 (0.35, 10.08) 1.000 2.38 (0.49, 6.8) 0.599
18 2.75 (0.57, 7.83) 1.45 (0.04, 7.81) NA 0.79 (0.02, 4.34) NA
19 5.5 (2.05, 11.6) 2.9 (0.35, 10.08) 1.000 4.76 (1.77, 10.08) 1.000
20 0 (0, 3.33) 0 (0, 5.21) NA 8.73 (4.44, 15.08) 0.016 ([)
21 0.92 (0.02, 5.01) 2.9 (0.35, 10.08) NA 1.59 (0.19, 5.62) NA
22 0 (0, 3.33) 0 (0, 5.21) NA 7.14 (3.32, 13.13) 0.032 ([)
23 0.92 (0.02, 5.01) 1.45 (0.04, 7.81) NA 2.38 (0.49, 6.8) NA
24 1.83 (0.22, 6.47) 5.8 (1.6, 14.18) 0.782 3.17 (0.87, 7.93) 0.808
25 3.67 (1.01, 9.13) 2.9 (0.35, 10.08) 1.00 0 (0, 2.89) NA
26 3.67 (1.01, 9.13) 0 (0, 5.21) NA 2.38 (0.49, 6.8) 0.808
27 2.75 (0.57, 7.83) 1.45 (0.04, 7.81) NA 1.59 (0.19, 5.62) 0.808
NA, <5 isolates, not tested.
a bin cluster.
Table 2
Serotype and ST diversity at each CSS
CSS-1 CSS-2 CSS-3
Serotypea 0.94 0.93 0.94
STa 0.96 0.96 0.96
a Diversity was assessed using Simpsons Diversity index (Dominance Index
Approximation), which represents the probability that two randomly selected
strains are the same, where 1 means they are different and 0 indicates they are the
same.
R.A. Gladstone et al. / Clinical Microbiology and Infection xxx (xxxx) xxx 5(zero of six BAPS17 isolates) and CSS-2/3 (five of five BAPS17 iso-
lates, p 0.002). Only one additional isolate, belonging to serotype
13, carried the macrolide efflux gene mef(E) [22].Discussion
MDAwith azithromycin for trachoma elimination in The Gambia
was associated with a short-term decrease in S. pneumoniae car-
riage [11]. To evaluate whether communities were repopulated
with the same strains following treatment or whether MDA gave
rise to previously suppressed clones, we compared pneumococcal
isolates sampled from communities before and after a third round
of MDA. Our results show little change in population structure
following a round of MDA in communities where the number of
circulating lineages was high and the prevalence of macrolide
resistance low.
The number of BAPS clusters we identified was higher than
other published carriage datasets using this approach, likely
reflecting the broader pneumococcal diversity in The Gambia with
small numbers representing numerous circulating lineages [19,20].
No changes in BAPS clusters were identified at CSS-2, suggesting
any change that MDA had on the population structure was shortPlease cite this article as: Gladstone RA et al., Mass drug administratio
structure of Streptococcus pneumoniae in the nasopharynx, Clinical Microlived, or that these changes were below our detection limit. Greater
variation was seen between CSS-1 and CSS-3, 6 months following
MDA. These changes could be a result of natural temporal fluctu-
ations [34] or seasonal change [35]; CSS-1 and CCS-2 were con-
ducted in the wet season while CSS-3 was carried out in the dry
season. Only BAPS20 and BAPS22, showed an increase between
CSS-1 and CSS-3. However, these changes were not associated with
macrolide resistance and are difficult to attribute to the MDA.
Macrolide resistance conferred by mef(A) was confined to
BAPS17; this lineage did not increase significantly following
treatment. However, the proportion of macrolide resistance iso-
lates within BAPS17 was higher at both CSS-2 and CSS-3, indi-
cating an increase after MDA. No macrolide resistance was
observed in CSS-1 in any BAPS cluster. We cannot rule out low-
level presence of macrolide-resistant BAPS17 strains circulating
in the community at CSS-1 due to the relatively small sample size
in the background of high diversity. BAPS17 ST1794 was only
observed once in a published international dataset [36] despite
inclusion of 1249 carriage isolates from The Gambia. BAPS17 iso-
lates belong to the Global Pneumococcal Sequence Cluster GPSC61
within which mef(A) and/or erm(B) were not detected, suggesting
GPSC61 is not typically associated with macrolide resistance.
Although the numbers are small, all isolates that carried macrolide
resistance genes concurrently carried the tetracycline resistance
gene tet(M) in a mobile genetic element. If MDA selects for strains
carrying mobile genetic elements, often encoding multiple anti-
biotic resistance genes, there is potential for increases in multi-
drug resistance [37]. Macrolide resistance was at undetectable
levels in this study before the intervention, in other settings with
established macrolide resistance in pneumococci, the potential for
rises in macrolide-resistant pneumococci after MDA with azi-
thromycin may be greater. Further studies with larger sample sizes
would be needed to adequately address this concern and would ben with azithromycin for trachoma elimination and the population
biology and Infection, https://doi.org/10.1016/j.cmi.2020.07.039
R.A. Gladstone et al. / Clinical Microbiology and Infection xxx (xxxx) xxx6important if azithromycin MDA were to be considered as an
intervention to reduce child mortality [5].
Only 75% of randomly selected pneumococcal isolates from the
carriage survey could be sequenced, due to insufficient growth. This
may have resulted in an underrepresentation of serotypes or STs
that are slow growing or otherwise less robust. The sample size
relative to the high pneumococcal diversity observed in our study
limited our ability to detect smaller changes in serotype and ge-
notype frequency following MDA. We did not have isolates ob-
tained before MDA in this study. We therefore cannot rule out that
the 3-year MDA programme, as a whole, affected pneumococcal
population structure, although it did not lead to a substantial in-
crease in macrolide resistance as only 6/304 (2%) carried macrolide
resistance genes. We only screened for known genetic de-
terminants of macrolide resistance, however, mef genes and/or
erm(B) have been reported to have a sensitivity of 97% and speci-
ficity of 99% for phenotypic resistance in pneumococci [36]. Finally,
the original pneumococcal carriage study was conducted in villages
where the majority of children under the age of 6 years had
received PCV-7 vaccination. As we do not hold vaccination data on
individual study participants, PCV-7 vaccination may have
impacted the results of the current study. It is known that PCVs do
not modify carriage rates, but altered the serotype distribution by
increasing non-vaccine serotypes [37,38]. Therefore, our findings
should be generalizable to other countries where MDA for
trachoma control and PCV vaccination are both a part of the public
health strategy.
In this study we observed few changes in pneumococcal popu-
lation structure. A small number of isolates had macrolide resis-
tance genes, but these were found on a mobile genetic element
carrying other antimicrobial resistance genes in MDR strains.
Further studies with larger sample sizes would be needed to
determine whether azithromycin MDA selects for MDR.Transparency declaration
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